14 completed, 1 terminated. 15 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 14, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Menactra®: new trials by email Literature Review of Menactra® trials Research Report on Menactra®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 224 | 2016-06-06 | 2018-01-08 |
| Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 834 | 2011-09-01 | 2014-11-18 |
| Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi | 139 | 2010-11-01 | 2012-06-25 |
| Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults Meningococcal vaccine GSK 134612, Menactra® - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1013 | 2010-08-19 | 2018-06-26 |
| Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26 Meningococcal polysaccharide diphtheria toxoid conjugate - Meningitis, Meningococcemia | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 181 | 2008-06-01 | 2016-02-15 |
| Dose Comparison Study of Menactra® in US Children Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 333 | 2008-06-01 | 2016-04-14 |
| Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate - Meningococcal Infections, Meningococcal Meningitis | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 216 | 2007-10-01 | 2013-09-20 |
| Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. Meningococcal vaccine 134612, Menactra® - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 873 | 2007-04-23 | 2018-06-08 |
| Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningococcal Meningitis, Tetanus | Phase 2 | Completed | Sanofi | 882 | 2006-10-01 | 2011-08-24 |
| Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® Polysaccharide Diphtheria Conjugate Vaccine - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 234 | 2006-01-01 | 2014-02-14 |
| Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 145 | 2005-12-01 | 2016-04-14 |
| Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®), A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®) - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 378 | 2004-12-01 | 2014-02-14 |
| Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcemia | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 241 | 2004-02-01 | 2014-02-14 |
| Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcemia | Phase 2 | Terminated | Sanofi Pasteur, a Sanofi Company | 18 | 2004-01-01 | 2014-02-14 |
| Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Haemophilus Influenzae Type b (Hib) vaccine - Meningitis, Meningococcemia | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 103 | 2003-08-01 | 2016-04-14 |
Meningococcal Infections (14) · Meningitis (11) · Meningitis, Meningococcal (4) · Diphtheria (1) · Poliomyelitis (1) · Tetanus (1) · Whooping Cough (1)
Sanofi Pasteur, a Sanofi Company (11) · GlaxoSmithKline (2) · Sanofi (2)
United States (12) · United Kingdom (2) · Canada (1) · Vietnam (1)